AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Diabetes Study to Treat A Population Previously Not at Target
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 598
- Registration Number
- NCT00747149
- Locations
- 🇨🇦
Research Site, Quebec, Canada
A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00747175
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00746382
AZD5672 Absolute Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD5672
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00746837
- Locations
- 🇬🇧
Research Site, Harrow, London, United Kingdom
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00746434
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
Phase 2
Completed
- Conditions
- Non Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00745875
- Locations
- 🇺🇦
Research Site, Uzngorod, Ukraine
🇧🇬research Site, Pleven, Bulgaria
Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder
Completed
- Conditions
- ObservationalNaturalistic
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2008-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00745966
- Locations
- 🇰🇷
Research Site, Kyunggi-do, Choonchun-si, Korea, Republic of
🇰🇷RFesearch Site, Dae-gu, Joong-gu, Korea, Republic of
TLESR-impedance Study in Patients
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00743444
A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00741689
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Uric Acid Study in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- GoutCoronary Artery Disease
- Interventions
- Drug: AZD6140Drug: Placebo to match AZD6140
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00738842
© Copyright 2025. All Rights Reserved by MedPath